increas
evid
atyp
respiratori
pathogen
chlamydophila
pneumonia
mycoplasma
pneumonia
may
contribut
pathogenesi
stabl
asthma
asthma
exacerb
postul
organ
may
contribut
inflamm
airway
possibl
activ
inflammatori
mechan
respiratori
tract
macrolid
class
antibiot
may
part
play
manag
asthma
exert
antiinflammatori
effect
chronic
inflam
airway
addit
antiinfect
action
ketolid
antibiot
may
also
similar
properti
paper
discuss
role
antibiot
manag
asthma
asthma
complex
multifactori
diseas
involv
interact
genet
suscept
exposur
environment
factor
allergen
pollut
lower
respiratori
tract
infect
latter
felt
involv
variou
level
natur
histori
asthma
acut
viral
infect
eg
rhinoviru
coronaviru
respiratori
syncyti
viru
rsv
parainfluenza
viru
influenza
viru
adenoviru
associ
asthma
exacerb
children
adult
acut
bacteri
infect
atyp
pathogen
mycoplasma
pneumonia
chlamydophila
c
pneumonia
also
associ
acut
asthma
exacerb
wherea
chronic
infect
agent
may
play
role
persist
asthma
mechan
associ
presenc
microorgan
airway
asthma
fulli
investig
like
involv
increas
suscept
infect
asthma
presenc
infect
augment
inflamm
lower
airway
like
correspond
author
tel
fax
email
address
sjohnston
imperialacuk
sl
johnston
yet
unproven
repeat
acut
infect
andor
chronic
infect
play
role
diseas
progress
via
increas
inflamm
result
airway
remodel
confirm
antimicrobi
therapi
may
role
diseas
interrupt
viciou
cycl
infectiondiseas
progress
evid
everyday
clinic
practic
indic
antimicrobi
inde
commonli
prescrib
patient
asthma
europ
unit
state
interestingli
attitud
find
littl
support
current
guidelin
recent
nation
asthma
educ
prevent
program
expert
panel
report
indic
antibiot
current
recommend
treatment
acut
asthma
exacerb
except
fever
purul
sputum
clear
evid
infect
present
advic
base
two
randomis
doubleblind
placebocontrol
parallelgroup
trial
test
routin
antibiot
administr
addit
standard
care
adult
paediatr
popul
asthma
exacerb
publish
time
write
rather
old
studi
found
associ
antibiot
treatment
improv
asthma
outcom
must
howev
note
studi
small
employ
penicillin
deriv
atyp
pathogen
pneumonia
c
pneumonia
show
extrem
poor
respons
asthmat
individu
increas
suscept
rhinoviru
infect
risk
invas
bacteri
infect
mechan
increas
suscept
infect
asthma
better
elucid
two
recent
publish
articl
author
show
defici
rhinoviru
induct
interferon
asthmat
primari
bronchial
epitheli
cell
interferon
also
alveolar
macrophag
highli
correl
rhinovirusinduc
asthma
exacerb
sever
airway
inflamm
viru
load
vivo
relat
bacteri
infect
lipopolysaccharid
induct
interferon
asthmat
macrophag
also
defici
correl
exacerb
sever
data
identifi
novel
mechan
suscept
infect
asthma
suggest
new
approach
prevent
andor
treatment
asthma
exacerb
c
pneumonia
pneumonia
infect
associ
asthma
associ
asthma
c
pneumonia
infect
first
put
forward
hahn
et
al
earli
pneumonia
infect
may
associ
longlast
dri
cough
associ
asthma
symptom
suggest
main
problem
hamper
full
understand
possibl
associ
c
pneumonia
pneumonia
infect
asthma
lack
standardis
sensit
specif
diagnost
method
inform
link
pneumonia
c
pneumonia
infect
acut
asthma
exacerb
gather
adult
children
relationship
acut
infect
atyp
pathogen
acut
asthma
exacerb
children
sought
sever
control
uncontrol
studi
vast
major
studi
concord
find
associ
atyp
bacteri
infect
asthma
exacerb
rate
identif
vari
asthma
episod
c
pneumonia
pneumonia
find
suggest
relationship
childhood
asthma
acut
pneumonia
c
pneumonia
infect
children
wheez
incid
acut
pneumonia
c
pneumonia
infect
increas
age
occur
mainli
year
age
studi
employ
serolog
cultur
molecular
biolog
identifi
acut
atyp
infect
carri
adult
patient
present
asthma
exacerb
evid
atyp
infect
found
studi
interestingli
one
trial
serolog
associ
c
pneumonia
acut
asthma
found
antiheat
shock
protein
hsp
antibodi
tradit
serolog
marker
lieberman
et
al
found
pneumonia
c
pneumonia
associ
hospitalis
acut
exacerb
bronchial
asthma
studi
wark
et
al
onethird
patient
acut
sever
asthma
show
rise
c
pneumoniaespecif
antibodi
consist
acut
infect
reinfect
reactiv
latent
infect
microorgan
subject
exhibit
intens
inflammatori
respons
assess
sputum
total
cell
count
neutrophil
count
eosinophil
cation
protein
level
compar
subject
acut
asthma
show
increas
c
pneumonia
antibodi
level
overal
avail
studi
adult
children
suggest
acut
c
pneumonia
andor
pneumonia
infect
may
play
signific
role
asthma
exacerb
addit
acut
exacerb
role
pneumonia
c
pneumonia
pathogenesi
chronic
asthma
also
extens
investig
accumul
evid
seroepidemiolog
studi
shown
mani
asthmat
elev
antibodi
level
c
pneumonia
pneumonia
propos
pathogen
caus
occult
chronic
lower
airway
inflamm
consequ
associ
pathogen
chronic
asthma
hypothesis
trial
address
possibl
relationship
atyp
infect
persist
asthma
children
found
posit
neg
result
cunningham
et
al
larg
prospect
studi
schoolag
children
asthma
show
chronic
c
pneumonia
infect
common
popul
occur
around
onequart
children
furthermor
frequenc
asthma
exacerb
report
child
month
studi
posit
associ
level
secretori
iga
toward
c
pneumonia
author
suggest
inflammatori
respons
chronic
c
pneumonia
infect
may
interact
allerg
inflamm
increas
asthma
symptom
howev
given
recent
knowledg
also
possibl
chronic
c
pneumonia
infect
marker
increas
suscept
infect
therefor
infectionassoci
exacerb
moreov
strong
evid
suggest
serolog
evid
c
pneumonia
pneumonia
children
hospitalis
acut
exacerb
asthma
associ
persist
asthma
symptom
perhap
persuas
evid
come
recent
studi
children
c
pneumonia
detect
pcr
cultur
bronchoalveolar
lavag
collect
asthmat
children
undergo
bronchoscopi
sampl
pcrand
cultureposit
respect
elev
total
ige
strongli
associ
lavag
cultur
posit
chlamydia
data
requir
confirm
larger
number
children
comparison
control
subject
indic
viabl
c
pneumonia
organ
frequent
present
lung
lavag
fluid
asthmat
paediatr
patient
larg
number
control
uncontrol
trial
investig
role
c
pneumonia
pneumonia
adult
patient
chronic
asthma
serolog
commonli
employ
diagnost
method
trial
observ
associ
atyp
infect
chronic
asthma
neg
result
record
minor
case
kraft
et
al
shown
asthmat
patient
exhibit
evid
pneumonia
airway
colonisationinfect
significantli
greater
frequenc
nonasthmat
subject
larg
studi
involv
subject
symptom
suggest
asthma
rhiniti
allergi
logist
regress
analysi
control
age
sex
smoke
show
asthma
significantli
associ
elev
igg
antibodi
level
c
pneumonia
interestingli
atop
nonatop
analys
separ
even
stronger
relationship
longstand
asthma
obtain
nonatop
group
ci
data
indic
involv
microorgan
develop
nonatop
asthma
report
studi
investig
preval
posit
serolog
atyp
bacteria
asthma
control
popul
howev
possibl
associ
chronic
atyp
bacteri
infect
asthma
sever
adult
also
hypothesis
uncontrol
studi
black
et
al
describ
asthmat
subject
igg
iga
antibodi
c
pneumonia
associ
asthma
sever
marker
posit
associ
found
antibodi
c
pneumonia
use
highdos
inhal
steroid
higher
daytim
symptom
score
invers
associ
fev
percentag
predict
control
studi
huitinen
et
al
also
found
invers
correl
c
pneumonia
antibodi
titr
hsp
iga
fev
valu
martin
et
al
report
one
comprehens
evalu
role
c
pneumonia
pneumonia
infect
patient
chronic
asthma
studi
asthmat
patient
posit
polymeras
chain
reaction
pcr
result
mycoplasma
n
chlamydia
speci
n
mainli
found
lung
biopsi
specimen
lung
lavag
fluid
contrari
normal
control
subject
posit
pcr
result
mycoplasma
speci
high
number
posit
studi
associ
c
pneumonia
pneumonia
chronic
stabl
asthma
correl
increas
antibodi
titr
organ
increas
asthma
sever
support
exist
relationship
atyp
infect
chronic
asthma
studi
recent
review
detail
given
posit
find
regard
infect
atyp
organ
exacerb
previous
diagnos
asthma
chronic
asthma
interest
specul
whether
infect
bacteria
may
associ
newonset
asthma
previous
healthi
subject
regrett
limit
number
studi
address
issu
hahn
et
al
found
patient
acut
c
pneumonia
infect
subsequ
develop
asthma
studi
period
group
later
found
patient
de
novo
wheez
evid
acut
infect
five
patient
went
develop
chronic
asthma
convers
studi
newli
diagnos
asthma
children
adult
fail
identifi
associ
c
pneumonia
antibodi
titr
pneumonia
infect
also
associ
initi
onset
bronchial
asthma
studi
recent
studi
children
evid
pneumonia
infect
time
first
asthma
attack
current
evid
insuffici
support
refut
role
atyp
pathogen
newonset
asthma
serolog
evid
increas
atyp
bacteri
infect
asthma
increas
steadili
year
recent
support
increas
detect
organ
mostli
molecular
method
biolog
basi
increas
suscept
atyp
bacteri
infect
howev
begin
emerg
studi
mous
model
c
pneumonia
pneumon
reveal
dramat
increas
patholog
recent
shown
secret
bonemarrowderiv
macrophag
control
infect
importantli
depend
recent
discoveri
type
iii
ifn
realis
almost
ident
properti
innat
immun
type
ifn
coupl
demonstr
individu
asthma
defici
type
iii
ifn
product
macrophag
respons
viral
bacteri
stimuli
provid
import
like
explan
increas
suscept
atyp
bacteri
infect
asthma
studi
determin
whether
macrophag
individu
asthma
also
defici
type
ifn
product
respons
bacteri
stimuli
determin
whether
type
iii
ifn
also
import
host
defenc
c
pneumonia
infect
type
type
iii
ifn
pneumonia
requir
confirm
theori
thu
increas
evid
increas
frequencypersist
atyp
bacteri
infect
asthma
recent
evid
provid
ration
biolog
basi
increas
suscept
therefor
import
understand
consequ
sever
acut
chronic
atyp
bacteri
infect
airway
inflamm
airway
remodel
asthma
investig
field
far
concentr
mainli
c
pneumonia
wherea
less
inform
avail
pneumonia
mechan
regul
possibl
role
atyp
pathogen
caus
acut
sustain
persist
airway
inflamm
recent
review
c
pneumonia
pneumonia
infect
may
particip
pathogenesi
asthma
differ
level
airway
interact
numer
cellular
element
within
lung
mast
cell
epithelium
endothelium
macrophag
smooth
muscl
fig
summaris
current
known
interact
c
pneumonia
pneumonia
differ
cell
type
present
airway
evid
describ
present
increasingli
strong
case
role
atyp
bacteri
infect
asthma
patient
contribut
caus
exacerb
sustain
increas
sever
chronic
asthma
erad
atyp
bacteria
airway
could
therefor
becom
import
aspect
asthma
treatment
addit
provid
import
evid
regard
asthma
treatment
trial
test
clinic
efficaci
antimicrobi
therapi
activ
c
pneumonia
pneumonia
asthma
patient
would
also
provid
evid
role
atyp
bacteri
infect
diseas
antibiot
exert
activ
atyp
bacteria
macrolid
includ
azalid
azithromycin
ketolid
telithromycin
tetracyclin
fluoroquinolon
would
logic
candid
drug
date
clinic
trial
asthma
mostli
employ
macrolid
ketolid
due
favour
tolerabilitysafeti
profil
excel
intracellular
accumul
characterist
studi
chronic
stabl
asthma
singl
recent
studi
also
examin
efficaci
acut
asthma
exacerb
hahn
treat
asthmat
patient
seroposit
c
pneumonia
doxycyclin
azithromycin
erythromycin
median
period
week
mean
fev
increas
treatment
howev
studi
placebo
group
subject
receiv
wide
varieti
addit
medic
vari
dose
thu
decreas
valid
result
black
et
al
perform
multicentr
random
doubleblind
placebocontrol
trial
studi
effect
week
treatment
roxithromycin
mg
twice
daili
subject
asthma
serolog
evid
c
pneumonia
infect
followup
continu
month
follow
treatment
interrupt
author
observ
signific
improv
even
pef
valu
end
treatment
differ
group
diminish
thereaft
suggest
reinfect
cessat
treatment
result
loss
benefit
followup
suppress
rather
erad
c
pneumonia
obtain
treatment
phase
cochran
review
macrolid
usag
chronic
asthma
perform
ninetyf
candid
studi
initi
identifi
due
entri
criteria
employ
randomis
placebocontrol
studi
macrolid
therapi
week
durat
five
studi
total
patient
eventu
includ
metaanalysi
author
found
overal
posit
effect
symptom
eosinophil
marker
inflamm
follow
macrolid
therapi
asthma
patient
trial
includ
metaanalysi
studi
patient
chronic
stabl
asthma
treat
clarithromycin
twice
day
placebo
week
patient
pcrposit
pneumonia
c
pneumonia
macrolid
treatment
improv
fev
reduc
airway
tissu
express
similar
improv
observ
receiv
placebo
receiv
macrolid
therapi
without
evid
infect
suggest
treatment
effect
relat
antimicrobi
antiinflammatori
activ
mycoplasma
chlamydia
organ
still
present
airway
seven
asthmat
subject
treatment
clarithromycin
two
subject
posit
pcr
find
treatment
author
suggest
macrolid
bacteriostat
difficulti
erad
organ
moreov
difficulti
may
result
chronic
state
infectioncolonis
experiment
evid
suggest
may
deriv
studi
kutlin
et
al
test
prolong
treatment
azithromycin
clarithromycin
levofloxacin
c
pneumonia
continuousinfect
model
observ
treatment
agent
concentr
compar
achiev
epitheli
line
fluid
reduc
elimin
c
pneumonia
continu
infect
cell
data
suggest
dosag
durat
antibiot
therapi
current
use
may
suffici
erad
put
chronic
c
pneumonia
infect
recent
studi
also
includ
metaanalysi
adult
patient
mildmoder
asthma
treat
one
azithromycin
tablet
daili
consecut
day
follow
mg
weekli
addit
week
placebo
treatment
azithromycin
result
improv
asthma
symptom
score
posttreat
followup
period
use
nonvalid
score
measur
symptom
daili
activ
scale
posit
iga
igg
c
pneumonia
baselin
associ
sever
asthma
symptom
followup
treatment
group
small
determin
whether
treatment
effect
restrict
evid
infect
final
studi
children
also
metaanalysi
esposito
et
al
studi
children
age
year
recurr
lrti
includ
wheez
acut
bronchiti
patient
randomis
receiv
azithromycin
mgkgday
day
weekli
week
togeth
symptomspecif
agent
symptomspecif
agent
alon
first
month
clinic
success
significantli
frequent
among
patient
receiv
azithromycin
differ
signific
group
patient
serolog
andor
pcr
evid
atyp
bacteri
infect
nasopharyng
specimen
howev
studi
placebo
control
may
therefor
subject
bia
multicentr
doubleblind
randomis
placebocontrol
clinic
studi
assess
efficaci
oral
telithromycin
mg
daili
day
supplement
standard
care
treatment
adult
patient
acut
exacerb
asthma
assess
c
pneumonia
andor
pneumonia
infect
cultur
serolog
pcr
includ
compar
placebo
telithromycintr
patient
clinic
relev
significantli
greater
reduct
asthma
symptom
treatment
period
larger
improv
baselin
end
treatment
pft
includ
fev
faster
median
time
reduct
symptom
sever
day
versu
day
greater
proport
complet
symptomfre
day
treatment
period
versu
studi
demonstr
statist
signific
clinic
substanti
benefit
associ
ketolid
antibiot
treatment
acut
exacerb
asthma
popul
patient
evid
c
pneumonia
andor
pneumonia
infect
effect
telithromycin
fev
statist
signific
patient
document
infect
baselin
patient
without
evid
infect
howev
magnitud
treatment
effect
fev
similar
infectionposit
neg
group
lack
statist
signific
latter
could
simpli
relat
smaller
number
patient
group
differ
infectionposit
neg
group
term
studi
outcom
mechan
benefit
remain
unclear
main
limit
studi
report
literatur
relat
patient
popul
size
sever
asthma
studi
atyp
bacteri
diagnost
test
appli
gener
studi
studi
mildmoder
asthma
treatment
effect
observ
small
studi
design
power
subgroup
analys
infect
versu
noninfect
steroid
versu
nonsteroid
treatment
sever
versu
mild
asthma
etc
approach
limit
use
result
obtain
hamper
interpret
studi
import
issu
probabl
relat
definit
infect
asthmat
logic
suggest
studi
indic
treatment
effect
like
greatestonli
observ
infect
atyp
bacteria
time
treatment
given
serolog
may
use
retrospect
defin
acut
infect
good
pair
serum
sampl
avail
howev
clearli
use
make
acut
treatment
decis
unless
decis
made
singl
acut
sampl
telicast
studi
suggest
singl
estim
igm
may
use
studi
clearli
requir
confirm
serolog
certainli
lower
specif
sensit
appli
chronic
infect
adult
previous
expos
high
igg
level
therefor
poor
indic
current
bacteri
presenc
possibl
though
iga
may
prove
use
assess
igg
molecular
biolog
techniqu
specif
sensit
use
right
sampl
appli
pcr
sputum
probabl
better
use
pharyng
swab
specimen
acut
infectionreactiv
obtain
goodqual
sampl
difficult
sputum
contain
pcr
inhibitor
appropri
process
requir
sputum
pcr
yet
studi
context
chronic
infect
pcr
peripher
blood
mononuclear
cell
far
best
biolog
approach
detect
chronic
infect
method
confirm
site
infect
addit
molecular
method
standardis
great
deal
work
requir
could
consid
clinic
use
also
import
defin
sensit
endpoint
studi
asthma
outcom
inclin
pulmonari
function
test
patientreport
symptom
score
outcom
proven
use
placebocontrol
studi
chronic
asthma
date
qualiti
life
use
rescu
therapi
may
also
use
insuffici
data
determin
outcom
sensit
chang
exacerb
frequenc
also
import
clinic
outcom
studi
chronic
asthma
term
acut
exacerb
studi
inclin
pulmonari
function
test
patientreport
symptom
score
outcom
proven
use
placebocontrol
studi
report
date
data
publish
use
qualiti
life
questionnair
acut
asthma
may
new
import
end
point
futur
studi
clear
urgent
need
studi
investig
role
therapi
direct
atyp
bacteri
infect
acut
chronic
stabl
asthma
studi
must
welldesign
randomis
placebocontrol
studi
studi
stabl
asthma
date
studi
mildmoder
asthma
given
potenti
risk
gener
resist
use
longterm
antibiot
therapi
potenti
benefit
term
respons
current
avail
therapi
potenti
relief
burden
diseas
believ
studi
moderatesever
asthma
warrant
addit
known
antiinflammatori
activ
macrolid
ketolid
hamper
evalu
antibacteri
activ
drug
thu
studi
need
larg
adequ
power
subgroup
analys
infect
versu
noninfect
subject
methodolog
defin
infect
need
comprehens
possibl
prefer
use
newer
serolog
techniqu
includ
igm
perhap
iga
well
molecular
techniqu
prefer
respiratori
sampl
studi
acut
exacerb
asthma
chronic
stabl
asthma
need
perform
children
adult
grow
bodi
clinic
evid
indic
atyp
pathogen
c
pneumonia
pneumonia
may
contribut
pathogenesi
acut
exacerb
asthma
chronic
stabl
asthma
also
like
chronic
persist
infect
andor
frequent
reactiv
agent
may
contribut
ongo
inflamm
airway
possibl
therefor
longterm
remodel
howev
definit
demonstr
causal
associ
atyp
bacteri
infect
asthma
still
lack
may
patient
asthma
particularli
set
impair
innat
immun
respons
prone
infect
agent
increas
burden
infect
may
contribut
diseas
sever
progress
vitro
studi
identifi
number
mechan
associ
chronic
c
pneumonia
pneumonia
atyp
bacteri
infect
may
contribut
maintain
chronic
airway
inflamm
bacteri
element
activ
transcript
factor
thu
prime
cellular
element
bronchial
tissu
epithelium
endothelium
monocytesmacrophag
smooth
muscl
cell
result
cascad
cytokin
releas
adhes
molecul
upregul
favour
cellular
influx
airway
persist
inflamm
airway
remodel
evid
accumul
indic
macrolid
antibiot
class
may
exert
properti
promot
sustain
repar
process
chronic
inflam
airway
properti
distinct
antimicrobi
activ
term
antiinflammatori
antiinflammatori
effect
manifest
lower
dose
usual
sever
week
treatment
sever
anim
inflamm
model
vitro
studi
use
human
cell
cultur
clinic
studi
better
defin
possibl
mechan
macrolid
exert
antiinflammatori
activ
although
largescal
doubleblind
randomis
studi
need
defin
true
clinic
impact
downregul
host
inflammatori
respons
treatment
trial
institut
test
whether
includ
specif
antibiot
class
target
toward
atyp
bacteria
would
associ
better
clinic
outcom
compar
standard
medic
asthma
ideal
shortterm
indic
eg
recoveri
exacerb
longterm
indic
number
exacerb
progress
diseas
follow
data
limit
number
studi
carri
far
indic
treatment
macrolid
associ
benefit
clinic
function
term
although
perhap
patient
document
atyp
infect
provid
treatment
prolong
sever
week
key
question
whether
even
prolong
antibiot
treatment
capabl
truli
erad
c
pneumonia
pneumonia
rather
simpli
temporarili
suppress
infect
refuel
longstand
reservoir
singl
studi
acut
exacerb
ketolid
antibiot
also
show
clear
benefit
studi
macrolid
ketolid
antibiot
acut
asthma
exacerb
requir
summari
addit
research
confirm
preliminari
result
therapeut
decis
regard
asthma
patient
futur
includ
potenti
addit
antimicrobi
agent
clearli
better
definit
patient
subset
like
benefit
treatment
optim
agent
time
durat
therapi
essenti
antimicrobi
treatment
may
recommend
outsid
clinic
research
trial
